QCLS
Q/C TechnologiesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About QCLS
Q/C Technologies, Inc.
A clinical stage pharmaceutical company dedicated to extending healthy lifespan
1185 Avenue of the Americas, Suite 249, New York, NY 10036
--
Q/C Technologies, Inc., was legally incorporated in New Jersey as A.R.C Enterprises, Inc., on March 9, 1989. On July 22, 2024, the company changed to a Delaware corporation. The company is a clinical-stage pharmaceutical company dedicated to extending healthy lifespan. TNF focuses on the development and commercialization of two therapeutic platforms based on clearly defined therapeutic targets, isosinosine and Supera-CBD.
Company Financials
EPS
QCLS has released its 2025 Q3 earnings. EPS was reported at -2.5, versus the expected 0, missing expectations. The chart below visualizes how QCLS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
